Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
BACKGROUND The increasing understanding of non-small cell lung cancer (NSCLC) biology over the last two decades has led to the identification of multiple molecular targets. This led to the development of multiple targeted therapies in the primary and secondary resistance setting and the epidermal growth factor receptor (EGFR) gene remains the most frequently observed molecular target in NSCLC. ...
متن کاملEGFR mutation testing in non-small cell lung cancer (NSCLC).
Lung carcinoma is subdivided into small cell carcinoma and non-small cell carcinoma (NSCLC). NSCLC is heterogeneous group of carcinomas and accounts for 70-80% of lung cancer. NSCLC is further divided into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been cha...
متن کاملPrimary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
PURPOSE We performed this analysis to improve the understanding of the clinicopathological characteristics and clinical outcome of non-small cell lung cancer (NSCLC) patients harboring the primary epidermal growth factor receptor (EGFR) T790M mutation along with activating EGFR mutation. METHODS Resected tumors from 1903 NSCLC patients were analyzed for mutation in EGFR, as well as KRAS (Kirs...
متن کاملThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, AS...
متن کاملEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lun...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Experimental Hematology & Oncology
سال: 2015
ISSN: 2162-3619
DOI: 10.1186/s40164-016-0052-3